# ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

> **NCT05062317** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (estimated)

## Conditions studied

- Liver Metastases

## Interventions

- **DRUG:** Leucovorin
- **DRUG:** 5-FLUOROURACIL
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05062317
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-26
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062317, "ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05062317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*